Albany Molecular Research (AMRI) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
AMRI Announces First Quarter 2017 Results
May 9, 2017 7:30 AM EDTALBANY, N.Y., May 9, 2017 /PRNewswire/ --Â AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2017 and provided an update to its outlook for 2017.
Highlights:
First quarter total revenue of $163.8 million, up 55% from 2016 First quarter basic and diluted EPS $(0.25); non-GAAP diluted EPS of $0.13 First quarter net loss of $(10.7) million; non-GAAP net income of $5.7 million First quarter adjusted EBITDA of $24.0 million, up 83% from 2016 Company confirms 2017 financial guidanceNon-GAAP net income, non-GAAP diluted EPS... More
